Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
KALA BIO INC (KALA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.15-14.37%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for KALA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
No further dilutive equity sales in 2026 | A supporting condition in KALA BIO INC's published investment case. The stated target is No new equity sales. | Under Pressure | New equity sales announced in next 4 quarters | Equity sales reported vs No new equity sales Unregistered equity sales (Mar 2026) and prospectus supplement (Jul 2026) indicate dilutive activity. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 18, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
KALA is a high-risk, loss-making business with a speculative multi-year view rather than an established durable compounder. The thesis is marked intact, with recent financial performance still in the top half of its industry, but the evidence is only medium confidence.
The valuation model describes KALA as cheap versus peers, while its expectations gap is negative and model confidence is low. The overall priced-in tag is justified, and no fragility gates fired, but the snapshot does not specify what investors specifically assume about future business results.
Near term, earnings risk is elevated, with a 58% estimated miss probability, and recent financial performance is rated neutral. Management announced a 1-for-50 reverse stock split to support Nasdaq listing compliance; later updates do not show that priority being revisited. A delisting notice and litigation filing add risk, while the debt issuance is listed as a neutral event.
Over the next few quarters, the thesis depends on whether KALA sustains its relative financial performance and makes progress on its watched priorities, including the Younet AI platform license. Healthcare sector momentum could support the setting if VRTX, REGN, and MRNA continue to report strong results and guidance, but misses or weaker guidance could remove that tailwind. Further weakening in the jobs report could also deepen recession concerns for cyclical names.
For the 1-3 year view, the thesis is intact but fragile in practice: losses, volatile management, elevated earnings risk, and listing and legal issues weigh against a sector backdrop that has improved. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in KALA BIO INC's published investment case. The stated target is >= -0.53 USD per share. |
| Intact |
| EPS loss worsens beyond -0.53 in FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue stabilizes above zero in FY26 | A primary condition in KALA BIO INC's published investment case. The stated target is > 0 USD. | Broken | Revenue remains at zero or declines further in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-20.00 → $-20.00 · observed estimates
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-07-25 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-07-26 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-07-27 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-07-28 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-07-29 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-07-30 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-07-31 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-01 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-02 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-03 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-04 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-05 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-06 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-07 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-08 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-09 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-10 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-12 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-13 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-14 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-15 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-16 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-17 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-18 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-19 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-20 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-21 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-22 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-23 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-24 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-25 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-26 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-27 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-28 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-29 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-30 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-08-31 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-01 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-02 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-03 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-04 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-05 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-06 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-07 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-08 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-09 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-10 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-11 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-12 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-13 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-14 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-15 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-16 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-17 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-18 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-19 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-20 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-21 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-22 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-23 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-24 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-25 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-26 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-27 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-28 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-29 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-09-30 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-01 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-02 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-03 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-04 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-05 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-06 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-07 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-08 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-09 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-10 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-11 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-12 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-13 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-14 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-15 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-16 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-17 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-18 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-19 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-20 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-21 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-22 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-23 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-24 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-25 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-26 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-27 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-28 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-29 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-30 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-10-31 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-11-01 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-11-02 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-11-03 | $-20.00 | $26,118,000 | 1 / 1 |
| 2026-11-04 | $-20.00 | $26,118,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.